Dr. Deepak Kumar Bandari, PharmD : Short Profile

Thank you for visiting my blog...!!!

Here you can check out my short profile 

Dr. Deepak Kumar Bandari, PharmD, (PhD) (Europe)

Research Scientist, ICMR-NICPR, Noida.

Current Position: National

1) Project Research Scientist - Indian Council of Medical Research (ICMR) - National Institute of Cancer Prevention and Research (NICPR), Noida and Delhi. 

Project: AccEEND TB, India.

2) Board of Studies Member - Master’s in Clinical Research and Experimental Medicine, School of Allied and Health Sciences, Malla Reddy University, Hyderabad.

3) Book reviewer - BSP Publications, Pharma Med Press and Kakatiya Publications.

Current Position: International
PhD Researcher and Early Stage Researcher participant
Project: FIP 7 programme of EuroAgeism H2020 project, involving 13 European and Non-European countries.

Early-Stage Researcher (ESR) Participant, Euro Ageism H2020, Faculty of Pharmacy in Hradec Králové, Charles University, Europe.

Thesis: Polypharmacy and comparison of differences in potentially inappropriate prescribing in India, Ethiopia, and European countries.
Projects and Grants handled: 

• Project: FIP 7 programme of EuroAgeism H2020 project, involving 13 European and Non-European countries.

Grant: European Commission, FIP7 program Euro Ageism H2020-764632-MSCA-ITN supported by the scientific group “Ageing and Changes in the Therapeutic Values of Drugs in the Aged”, Charles University, Progress Programme Q42, SVV program 260 417.
Total Finance - 232 422,48 EU (Detailed budget - not disclosed)
EU Consortium: Israel, Czech Republic (CZ), UK, Poland, Netherlands, Sweden, Finland, Belgium.
Participating countries: Czech Republic, Serbia, Croatia, Bulgaria, Estonia, Turkey, Spain, Ireland, Belgium, India, Ethiopia.
Collaborating Institutions: Alliance Health and Social Care Alliance Scotland (AL), EMDA – The Alzheimer’s Association Israel (AAI), European Centre for Social Welfare Policy and Research (Euro Centre), National University of Ireland Galway (NUIG), United Nations Economic Commission for Europe (UNECE) and World Health Organization (WHO).

• Project No. START/MED/093

Thesis: Rational geriatric pharmacotherapy, medication errors and clinical pharmacy services in long-term care.
Total Finance - 2,299,968 CZK (Personal cost-1,353,600; Mentor remuneration-40,000; Travel costs-361,000; Training costs- 120,000; Costs of non-investment equipment, materials etc. - 80,000; Overhead costs - 345,368)
Grant: Charles University, Research Unit “Ageing, Polypharmacy and Changes in the Therapeutic Value of Drugs in the AgeD”, United Nations Economic Commission for Europe and World Health Organization, University of Zagreb, Croatia, University of Belgrade.

Previous Positions: National

1)Project Technical Support - III (Field Investigator) - Indian Council of Medical Research (ICMR) - National Institute of Nutrition (NIN), Hyderabad, India. 

Project: Strengthening the Monitoring of Tuberculosis Elimination in India - District Level Sentenial Survey (DLSS), India.

2) Associate Consultant (Epidemiology and Outcomes Research) - Bridge Medical Consulting Pvt. Ltd, New Delhi. 

3) Team Leader - Indian Council of Medical Research (ICMR) – National Institute of Nutrition (NIN), Hyderabad, India.

Project: National Sero-surveillance to monitor the trend of SARS-CoV-2 infection transmission in India.

4) Investigator (Field) - Indian Council of Medical Research (ICMR) – National Institute for Research in Tuberculosis (NIRT), Chennai, India.

Project: National survey for the state-wise prevalence of microbiologically confirmed pulmonary tuberculosis in India.

5) Assistant Professor and Clinical Preceptor: Vaagdevi Institute of Pharmaceutical Sciences, Warangal, India. 

No. of Research Publications: 18
Cumulative Impact Factor: 153
Number of Citations: 3000+

h-index: 14; i-10 index: 15 

Awarded grants: Total 7 (International: 6, National: 1)
Achievements: Total 9 (International: 5, National: 4)
My Interviews in Magazines and Newsletters: 3 (International: 2, National: 1)

Scientific presentations: (International: 11, National: 8)
Book reviews: 9 (International: 2, National: 7)
Guest Lectures: Total 3 (International: 1, National: 2)
Editorial member and reviewer: 8
Certification courses: Total 10 (2 - Stanford University, 8 - National and International Organizations)
Countries affiliated: USA, Italy, Poland, Slovak Republic, The Czech Republic, Germany, Hong Kong and 10 other European countries.

International collaborative research: Early Stage Researcher participant in the FIP 7 programme of EuroAgeism H2020 project under Marie-Curie Innovative Network and EU COST Action IS1402 network aimed at describing main prescribing problems in rational geriatric pharmacotherapy in 13 European and Non- European countries (including India and Ethiopia). 

Collaborating Institutions: Alliance: Health and Social Care Alliance Scotland (AL), EMDA – The Alzheimer’s Association Israel (AAI), European Centre for Social Welfare Policy and Research (EuroCentre), National University of Ireland Galway (NUIG), United Nations Economic Commission for Europe (UNECE) and World Health Organization (WHO).

Remarkable Achievements:

1. Award and Position: Early Stage Researcher (ESR) participant in the network of FIP7 EuroAgeism H2020 – ITN project, European Commission.
2. Reviewer: Acknowledged in Davidson’s Principles and Practice of Medicine textbook, 23rd Edition, 2018; Elsevier publishers ISBN: 9780702070280.
3. Personal interview: “I expect the 8-star Pharmacist Concept of World Health Organization will come true in India in the Future” published in an International Magazine “Lekarnicke Listy”, March 2018, Bratislava, Slovak Republic.
4. Best reviewer award: Textbook of Hutchison’s Clinical Methods 23rd International Edition by Michael Glynn &William Drake. Saunders Publishers, UK ISBN: 978-0-7020-4091
5. ERASMUS+ Student Mobility: Internship in various European countries.

A few other Achievements:

1. Award and Interview: Winner of “Ideathon” First Nobel Prize Series in India, Department of Biotechnology, India. Interview entitled “Pharmacist Nobel Prize Series: Science Impacts Lives – The Pride of India”, Indian Pharmaceutical Association – Community Pharmacy Division (IPA - CPD) e-Times 6 (2), March – April 2017.

2. Story of Success (2017): Published by Elsevier, as a part of the budding Medicos National contest.

3. Elsevier Student Ambassador (ESA) and Mentor’ for South Asia from July 2014 to June 2016.

4. Felicitation and award: Special Faculty Achievement Award at Viswambhara Educational Society Silver Jubilee Celebrations, March 2018, Warangal, India.

5. Award: Pharmacy Practice contribution award on World Pharmacist’s Day, 25th September 2017 for the successful delivery of an invited lecture on the Prescriptive role of Clinical Pharmacist in Ambulatory Care at Deccan School of Pharmacy, Hyderabad, India.

Acknowledgement: 

• I thank Prof. Daniela Fialova, PharmD, PhD, BCCP; Chair of the Horizon 2020 EuroAgeism FIP7 program; Head of the University Centre of Clinical Pharmacy, Faculty of Pharmacy, Charles University; Department of Social and Clinical Pharmacy, Faculty of Pharmacy, Charles University, Department of Geriatrics and Gerontology,1st Faculty of Medicine, Charles University, Czech Republic.
• Dr Akshaya Srikanth Bhagavathula, PharmD, PhD; Associate Professor of Epidemiology, Department of Public Health, North Dakota State University, United States of America. 
• Prof. Yamsani Madhusudan Rao, M.Pharm, PhD; Director, Vaagdevi group of Pharmacy Colleges, Warangal, India for their valuable guidance and support throughout my career.

 

 Public Health Research Initiative (PHRI) Research Grant: 2016-17

Dear Readers..!!! Thanks for visiting my blog...!!!

Public Health Research Initiative (PHRI)

Public Health foundation of India (PHFI) in collaboration with Science and Engineering Research Board (SERB, A Statutory Body under Department of Science and Technology (DST)) aims to set up anextramural fund to provide the Indian researchers focused on public health from institutions of repute, as per an established process. PHRI will enable young Indian researchers to carry out clearly defined research project at a place of their choice up to a period of 36 months.

Project Duration and Cost

These grants will be awarded for research studies of public health importance in India. The estimated amount of the available research grant is limited to 30 Lakh INR per Research Grant. The total duration of the grant will not exceed more than THREE years.

Eligibility Criteria

The applicant must possess a Post-Graduate degree from an accredited institution in any domain related to public health, including medical and non-medical sciences, nutrition, physiotherapy, dentistry, pharmacy, nursing, social sciences, law and humanities. It would be desirable if the applicant has a doctoral degree. (Applications related to Biomedical, Biophysics and biochemistry are excluded from PHRI Research Grants)

Age Criteria

The applicant must be 40 years or less at the time of applying for the PHRI Research Grant, age relaxation of 5 years is applicable for female or if applicant belong to SC/ST/OBC then

Application procedure:

Candidates are requested to apply online

a) Online application formats with detailed guidelines are available at the website www.phfi.org Guidelines for Submitting a proposal

This should include the following

1. Title of the study
2. Overall goal
3. Broad Objective
4. Specific objectives
5. Methodology
6. Analysis plan
7. Expected outcome
8. Timeline
9. Implications for future research
10. References
11. Dissemination and publication plan
12. Itemized budget along with justification for each item
13. Curriculum vitae of investigator listed in the grant application

Word limit: Not more than 3000 words (excluding references, Dissemination plan, Itemized budget and Curriculum Vitae) Font Style: Times New Roman Font Size: 12 with Line Spacing 1.5

Kindly note following should be mentioned while sending the grant application:

Area of work:

Area proposed by candidate should be clearly defined research area in any aspect of Public Health like Public Health Nutrition, Non Communicable Diseases, Infectious Diseases and Public Health Policy etc.

Place of work:

A project site in India, depending on the demand of the research study.

The PHFI reserves the right to reject the Research Grant application in case candidate DOES NOT FULFILL minimum qualification or supplies any false information.

Public Health Research Initiative (PHRI) Research Grant: 2016

Online submission will close by 30 June 2016 after 5:00 PM.

Apply Here

Happy Blogging...!!!

Free Online Course : Preventing the Zika Virus

Dear Readers..!!! Thanks for visiting my blog...!!!

About the Course:

The Zika virus is suspected to be the cause of cases of microcephaly in newborns in South America, and this outbreak has now been declared a Public Health Emergency of International Concern by the World Health Organization. With global attention towards this disease increasing rapidly, it is becoming clear that there is limited knowledge around how the carriers, or vectors, of Zika, are best avoided and controlled.

Focus on the Zika virus:

This free online course will begin by considering the science behind the outbreak to try to understand where the Zika virus has come from, its symptoms, and its effect on infected individuals. Our attention will then turn towards the vector primarily responsible for transmission of Zika: theAedes mosquito.

Explore the biology of Aedes mosquitoes:

We will introduce the Aedes mosquito and examine its lifecycle, behaviour, and distribution across the world, before reflecting upon the important role it plays in spreading Zika virus. Without a vaccine, prevention and control relies on reducing numbers of mosquitoes and the contact they have with people, so an understanding of the biology of Aedes is vital.

Discover vector control methods:

A range of methods employed to control the Aedes mosquito will be highlighted, including the use, importance, and suitability of repellents, impregnated clothing, larval control, insecticide spraying, and insecticide treated nets. The vectors of Zika virus also transmit dengue, yellow fever and the chikungunya virus, meaning there is potential to apply these techniques in other settings.

Learn together and from those on the front line in South America

Learners will come from all over the world with their own diverse experiences and interests. You will have the opportunity to exchange thoughts and ideas through course discussion, and hear first-hand accounts from experts and individuals working in the field in South America. 

Contributors include:

1. Dr Mary Cameron, Reader in Medical Entomology
2. Dr Jo Lines, Reader of Malaria Control and Vector Biology
3. Professor Laura Rodrigues, Professor of Infectious Disease Epidemiology and working with the Microcephaly Epidemic Research Group in BrazilProfessor Jimmy Whitworth, Professor of International Public Health.

Support for Portuguese and Spanish speakers will be available throughout the course, including video subtitles, transcripts, and translations of other key materials.

About ARCTEC:

ARCTEC is an integral part of the Department of Disease Control at the London School of Hygiene & Tropical Medicine and a world-leading independent test centre for consultancy and the evaluation and development of arthropod pest control technologies.

REQUIREMENTS:

This course is designed for anyone with an interest in learning about Zika virus vector control. It is relevant to workers newly drafted into vector control work, NGO employees in affected countries, students taking a healthcare or science-related degree, medical students and postgraduates wishing to complement their studies, and academic staff in aligned disciplines.

Join the Course Here

For more Updates, follow us on Facebook. 

Happy Blogging...!!!

Regards,

Deepak Kumar Bandari,

Pharm.D Intern,

Vaagdevi College of Pharmacy - India

Elsevier Student Ambassador - South Asia

New Study Reveals Tamoxifen Reduces Breast Cancer Rates by Nearly a Third for 20 Years

Dear Readers..!!! Thanks for visiting my blog...!!!

A new study has shown that the preventive effect of the breast cancer drug, tamoxifen, remains virtually constant for at least 20 years, with breast cancer rates reduced by around 30 percent. Median 16-year follow-up results from the IBIS-I (International Breast Cancer Intervention-I) trial show a 29% lower risk for developing breast cancer among women who had been randomly assigned to five years of tamoxifen than for women assigned to five years of placebo.

“Tamoxifen is a well-established and effective treatment for certain breast cancers, but we now have evidence of its very long-term preventive benefits…" said Professor Jack Cuzick, IBIS-I lead author and Head of the Centre for Cancer Prevention at Queen Mary University of London. Professor Cuzick underscored the “strong and unabated” 20-year preventive effect of breast cancer resulting in a reduction in breast cancer rates of around a third. “We hope these results will stimulate more women, particularly younger women, to consider treatment options for breast cancer prevention if they have a family history of the disease or other major risk factors.”

The IBIS-I results were presented on December 11, 2014 at the San Antonio Breast Cancer Symposium (SABCS 2014) in Texas and published simultaneously in The Lancet Oncology. SABCS is an international scientific symposium for interaction and exchange among basic scientists and clinicians in breast cancer.

It was organized by the Cancer Therapy & Research Center at UT Health Science Center San Antonio, the American Association for Cancer Research, and Baylor College of Medicine. The IBIS-I study, which began recruitment in 1992, enrolled 7,154 pre- and post-menopausal women aged from 35 to 70 years at high risk for breast cancer primarily because of a family history. They were randomly assigned to receive either tamoxifen 20 mg daily for five years (3,579) or placebo (3,575).

Hormone replacement therapy was allowed during the trial and was used by 49.5% in the placebo group, and approximately 35% of women in each group had had a hysterectomy. The median age at enrollment was 50.8 years in each group. At a median of 16 years of follow-up (longest follow-up 22 years), there were 601 breast cancers reported, 251 (7.0%) occurring in women who took tamoxifen, and 351 (9.8%) in women who took placebo.

In subanalysis, the most pronounced reductions in risk were seen for invasive estrogen-receptor-positive (ER+) breast cancer and ductal carcinoma in situ. However, tamoxifen did not significantly reduce the risk for invasive estrogen-receptor-negative (ER-) breast cancer. The extended analysis of the IBIS-I trial was announced a year after the first results of the IBIS-II trial were released, which found taking the breast cancer drug anastrozole (an aromatase inhibitor) for five years reduced the chances of post-menopausal, high-risk women developing the disease by 53% compared with women who took a placebo. Professor Cuzick concludes: “For most post-menopausal women, an aromatase inhibitor such as anastrozole should be the drug of choice, as it is more effective than tamoxifen and has fewer side effects. However… “…for most premenopausal, high-risk women, tamoxifen remains the only drug of choice for breast cancer prevention and it is a good one, as shown by this new evidence.”

Most Filipino patients cannot afford cost of breast cancer screening, treatment

In the Philippines, which has the highest rate of breast cancer in Asia, low awareness may not be the main reason why the majority of breast cancer cases are not diagnosed early. “Most Filipino patients cannot afford the cost of diagnostic tests and treatments for breast cancer,” states the 2010 Philippine Cancer Facts and Estimates, a document published by the Department of Health and Philippine Cancer Society.

Experts recommend that women, starting at the age of 30, perform monthly self breast examination (SBE) and undergo an annual clinical breast examination (CBE) performed by a healthcare professional. Annual mammogram is recommended for women beginning age 40. According to the 2010 Philippine Cancer Facts and Estimates, national breast cancer awareness campaigns which do not include the provision of diagnosis and treatment are outdated and ineffective. It recommended that each province, city, municipality and barangay should establish and implement its own program for breast cancer diagnosis and treatment.

For such a program to succeed and be sustainable, local government officials, insurance providers, NGOs and civic-minded individuals and organizations, health workers and medical specialty societies must work together in providing access to breast cancer screening and treatment.

References:

1. http://www.medscape.com/viewarticle/836478

2. http://www.qmul.ac.uk/media/news/items/smd/144949.html

3.http://www.mayoclinic.org/diseases-conditions/breast cancer/basics/symptoms/con-20029275

4. http://www.philhealth.gov.ph/news/2012/z_benefits.html

For more Updates, follow us on Facebook. 

Happy Blogging...!!!

Regards,

Deepak Kumar Bandari,

Pharm.D Intern,

Vaagdevi College of Pharmacy - India

Elsevier Student Ambassador - South Asia

e­‐Learning in Public Health Management

Dear Readers..!!! Thanks for visiting my blog...!!!

e-learning in Public Health Management (ePHM) course is the flagship course of e-learning at IPH. Started with the primary aim of capacity building of district and block programme managers in NRHM who largely come from management or non-public health background, this course was envisioned to introduce the target group to basic concepts of Indian public health system and also to train them in effectively managing the day to day activities of a district/ block health setup. This course was simultaneously also introduced to professionals who were not a part of the government health set up yet worked in close association with it.

Following two batches and several suggestions and inputs later, the consensus was that the level of the course though appropriate for a novice in the field of public health, is too basic for those who have prior experience. To remedy this (keeping in mind the entry level public health professionals) we have redesigned the ePHM course with retention of the basic components along with addition of advanced topics such as health systems, health management concepts etc for those who want to do understand public health care more in depth. This document presents a detailed description of the structure of the course with brief description of the topics that will be covered.

Structure of the Course: The new version of ePHM course has been designed to cater to the needs of both the entry level as well as mid-career public health professionals. The design of the course is such that it gives the option of incremental learning to the student so that he/she can choose till what level he would like to learn and will be awarded a certificate accordingly.

The course consists of two levels –
Level 1: Introductory concepts of Indian Public Health System and
Level 2: Advanced concepts of Public Health Systems including public health management.

The entire course is divided into 8 modules. Each module consists of four units. Each student has the option of attending a small test before starting each module. This is a test of diagnostic nature consists of questions covering the important topics to be taught in Unit 1 and 2.

If the student is able to answer more than 80% of the questions correctly then he can directly proceed to the advance units of 3 & 4 and can skip the first two units.

This process is aimed at helping students identify the topics that they already are familiar with and giving them an opportunity to directly learn the advanced topics without redoing the basics.

Public Health : 100 Global Health issues

Dear Readers..!!! Thanks for visiting my blog...!!!

Today, I would like to list out 100 important global health issues that are covered under Public health.

I have come across many students making fun of Public health, when asked what is public health they say.. "it is health of public and why you are asking it when it is so simple". Let me add few points for their innocence.

What is Public health?

Public health refers to all organized measures to prevent disease, promote health, and prolong life among the population as a whole. Its activities aim to provide conditions in which people can be healthy and focus on entire populations, not on individual patients or diseases. Thus, public health is concerned with the total system and not only the eradication of a particular disease. 

The three main public health functions are:

• The assessment and monitoring of the health of communities and populations at risk to identify health problems and priorities.
• The formulation of public policies designed to solve identified local and national health problems and priorities.
• To assure that all populations have access to appropriate and cost-effective care, including health promotion and disease prevention services.

Public health is all around us: the water we drink, the immunizations we receive and the environment in which we live in..  

List of various Global health issues covered under Public Health:

1. Adolescent health
2. Ageing
3. Bacterial diseases
4. Biological issues
5. Biosafety
6. Blood transfusion safety and blood products
7. Cancer
8. Cardiovascular diseases
9. Chemical Safety
10. Child and Maternal health
11. Communicable diseases
12. Diabetes
13. Diarrhoeal diseases and Cholera
14. Disabilities and Rehabilitation
15. eHealth
16. Emergency and Humanitarian action
17. ePortuguese programme 
18. Environmental and Humanitarian action / hazards
19. Ethics
20. Event based surveillance 
21. Evidence informed policy making
22. Filarial infections
23. Finance
24. Food safety
25. Gender, Women and Health
26. General management
27. Genetics and hereditary diseases
28. Global health observatory
29. Global Learning and performance management
30. Global mass gathering
31. Health economics and financing
32. Health information, statistics, measurement and trend assessment 
33. Health legislation and human rights
34. Health promotion and education
35. Health security
36. Health systems research and development
37. Health technology (laboratory services)
38. Healthy cities
39. Hepatitis
40. HIV/AIDS
41. Human Resources management
42. Human resources for health (excluding Nursing)
43. Immunology
44. Influenza
45. Informatics and telemedicine
46. Information technology and telecommunications
47. Injuries, violence and accident prevention
48. International health regulations
49. Laboratory biorisk management
50. Laboratory biosecurity
51. Legal
52. Leishmaniasis
53. Leprosy
54. Library services and publishing
55. Malaria
56. Mental health and Neurosciences
57. Monitoring and Evaluation
58. Non-communicable diseases
59. Nursing
60. Nutrition
61. Occupational health
62. Oral health
63. Organ transplantation
64. Outbreak alert and response
65. Parasitic diseases
66. Patient safety
67. Pharmaceuticals (Essential drugs and Medicines)
68. Planning, Resource coordination and Performance monitoring 
69. Poliomyelitis
70. Prevention of Blindness
71. Prevention of Deafness
72. Public Health Emergency
73. Rabies
74. Radiation
75. Reproductive health
76. Research policy and development
77. Respiratory infections
78. Rheumatic diseases
79. Risk assessment
80. Risk communication
81. Safety measures in Microbiology
82. Schistosomiasis
83. Security management
84. Sexual Transmitted Diseases
85. Small pox
86. Social determinants of health
87. Suicide prevention
88. Substance abuse (alcohol and drugs)
89. Surgical care
90. Tobacco
91. Tourist health and travel medicine
92. Traditional medicine
93. Trypanosomiasis
94. Tuberculosis
95. Vaccines
96. Vector biology and control
97. Viral diseases
98. Viral hemorrhagic fevers
99. Water and sanitation
100. Zoonoses.

For more Updates, follow us on Facebook. 

Happy Blogging...!!!

Regards,

Deepak Kumar Bandari,

Pharm.D Intern,

Vaagdevi College of Pharmacy - India

Elsevier Student Ambassador - South Asia

Public Health Research Initiative (PHRI) Research Grant: 2015-16

Dear Readers..!!! Thanks for visiting my blog...!!!

Dear Pharm.D Professionals,

Finally, the wait is over now its time to prove.. This is a challenging opportunity to prove the strength of Indian research in Global Public Health, If we get succeed in this.. there exists many more opportunities. 

All the Best.

Public Health Research Initiative (PHRI)

Public Health foundation of India (PHFI) in collaboration with Science and Engineering Research Board (SERB, A Statutory Body under Department of Science and Technology (DST)) aims to set up an extramural fund to provide the Indian researchers focused on public health from institutions of repute, as per an established process. PHRI will enable young Indian researchers to carry out clearly defined research project at a place of their choice up to a period of 36 months.

Project Duration and Cost:

These grants will be awarded for research studies of public health importance in India. The estimated amount of the available research grant is limited to 30 Lakh INR per fellowship. The total duration of the grant will not exceed more than THREE years.

Eligibility Criteria:

The applicant must possess a Postgraduate degree from an accredited institution in any domain related to public health, including medical and non-medical sciences, nutrition, physiotherapy, dentistry, pharmacy, nursing, social sciences, law and humanities. It would be desirable if the applicant has a doctoral degree. (Applications related to Biomedical, Biophysics and biochemistry are excluded from PHRI fellowships)

Age Criteria:

The applicant must be40 years or less at the time of applying for the PHRI Research Grant, age relaxation of 5 years is applicable for female or if applicant belong to SC/ST/OBC then

Application procedure:

Candidates are requested to apply online

a) Online application formats with detailed guidelines are available at the website www.phfi.org Guidelines for Submitting a proposal

This should include the following:

Title of the study

Overall goal

Broad Objective

Specific objectives

Methodology

Analysis plan

Expected outcome

Timeline

Implications for future research

References

Dissemination and publication plan

Itemized budget along with justification for each item

Curriculum vitae of investigator listed in the grant application

Word limit: Not more than 3000 words (excluding references, Dissemination plan, Itemized budget and Curriculum Vitae) Font Style: Times New Roman Font Size: 12 with Line Spacing 1.5

Kindly note following should be mentioned while sending the grant application:

Area of work:

Area proposed by candidate should be clearly defined research area in any aspect of Public Health like Public Health Nutrition, Non Communicable Diseases, Infectious Diseases and Public Health Policy etc.

Place of work:

A project site in India, depending on the demand of the research study. The PHFI reserves the right to reject the fellowship application in case candidate DOES NOT FULFIL minimum qualification or supplies any false information.

Public Health Research Initiative (PHRI) Fellowship: 2015. Online submission will close by 15 June 2015 after 5:00 PM.

Click here to apply for Grants

For more Updates, follow us on Facebook. 

Happy Blogging...!!!

Regards,

Deepak Kumar Bandari,

Pharm.D Intern,

Vaagdevi College of Pharmacy - India

Elsevier Student Ambassador - South Asia

68th World Health Assembly : A Debut free access for all

Dear Readers..!!! Thanks for visiting my blog...!!!

India assumes Presidency again, after 19 years - Pride for India if  the assumption comes true...

Today, I would like to discuss about World Health Assembly, its objectives, its impact on member states and its influence on developing countries. 

What is World Health Assembly??

World Health Organization (WHO) is the only International Organization with universal political legitimacy on global health issues. World Health Assembly is the supreme decision-making body that determines the policies of WHO with delegations from 194 Member States and with an Executive board of 34 technically qualified professionals of highest level of health to approve the proposed budget. The 1st Assembly was held in 1948 and the 68th session of the World Health Assembly takes place in Geneva, Switzerland from 18th May - 26th May 2015. Currently there are over 700 WHO collaborating centres in over 80 Member States working with WHO in different areas like nursing, occupational health, communicable diseases, nutrition, mental health, chronic diseases and health technologies.

Objectives of World Health Assembly??

Reforms will be made in every assembly for effective health promotion to achieve these common objectives: (Mentioned in simple and precise  manner for easy understanding to students)

1. To establish an effective collaboration with the United Nations, specialized agencies, governmental health administrations and professional groups.
2. Strengthens health services all over the world by assisting respective Governments.
3. Furnishes technical assistance and, in emergencies, necessary aid upon the request or acceptance of Governments.
4. Establishes and maintains administrative and technical services like epidemiological and statistical data.
5. Promotes maternal and child health and welfare and to foster the ability to live harmoniously in a changing total environment.
6. Promotes the prevention of accidental injuries.
7. Stimulates advance work to eradicate epidemic, endemic and other diseases.
8. Promotes the improvement of nutrition, housing, sanitation, recreation, economic or working conditions and other aspects of environmental hygiene.
9. Promotes co-operation among scientific and professional groups which contribute to the advancement of health.
10. Provides information, counsel and assistance in the field of health.
11. Assists in developing an informed public opinion among all peoples on matters of health.
12. Establishes and revise international nomenclatures of diseases, of causes of death and of public health practices.
13. Standardized diagnostic procedures as necessary.
14. Develops, establishes and promote international standards with respect to food, biological, pharmaceutical and similar products.

Benefit to India:

According to the reports of WHO, India shows a 100% collaboration with the World Health Organization and 68th World Health Assembly lead by India at Geneva from May 18-27, 2015. India assumes the Presidency in 68th World Health Assembly after 19 years. This event is expected to deliberate on the plan of action on innovation and intellectual property and other key issues of global interest including antimicrobial resistance, air pollution and health, global health emergency. This collaboration will set up working relations and standards in areas like:

1. Food safety
2. Nutrition
3. Nursing and Midwifery
4. Communicable diseases
5. Traditional medicine
6. International Classification 
7. Tobacco control
8. Radiation
9. Health promotion
10. Occupational Health
11. Deafness prevention

The Minister of Health & Family Welfare Jagat Prakash Nadda will preside over the 68th Session of the World Health Assembly. The Union Minister is leading a high level Indian delegation to the WHA, to be held in Geneva during 18-27 May, 2015 - Says the Political sources.

Debut Live Webcast:

For the first time, WHO provides the ability to remotely follow the work of the sixty-eighth session of the World Health Assembly live. The live webcast will begin on 18th May at 2pm IST to 26th May. For webcasting go through this link at the mentioned time.

Link for Webcasting : A free access to World Health Assembly

For more Updates, follow us on Facebook. 

Happy Blogging...!!!

Regards,

Deepak Kumar Bandari,

Pharm.D Intern,

Vaagdevi College of Pharmacy - India

Elsevier Student Ambassador - South Asia